The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

Professor Yvonne Bryson of the University of California Los Angeles described the new case at the conference and an accompanying press briefing. The middle-aged (post-menopausal) woman, a participant ...

The British HIV Association (BHIVA) has recommended that everyone living with HIV aged 40 and over should take a statin to reduce their risk of heart disease, even if they do not have raised ...

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the ...

Mpox looked like a very different disease among people with uncontrolled HIV, according to Orkin. “When I saw the fatality rate, I felt horrified,” she said. “If there’s someone in your life who ...

Over half of funding for anti-gender actors in Europe appears to come from within Europe itself, with significant amounts of money also flowing from the US and the Russian Federation, according to ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

In some cases, HIV can bypass the barrier that encases the brain and cerebrospinal fluid which can contribute to brain inflammation and neurocognitive symptoms. However, diagnosing this viral ‘escape’ ...

Research from specialist HIV prevention and treatment clinics for female sex workers in Nairobi has found that the number testing positive for HIV dropped by more than two-thirds between 2008 and 2017 ...

An Israeli biotech company has issued a misleading press release which has encouraged some media outlets to falsely suggest that a new drug, Gammora, may be able to cure HIV. Zion Medical report that ...

Budigalimab, a monoclonal antibody that blocks the PD-1 receptor on immune cells, was associated with delayed HIV rebound or sustained low viral load in a majority of people who interrupted ...

In 2019, South Africa adopted dolutegravir / lamivudine / tenofovir (TLD) as its preferred first-line regimen, replacing a regimen known as TEE or tenofovir / emtricitabine / efavirenz for most adults ...